Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lifelong TKI therapy: how to manage cardiovascular and other risks
Michael J. Mauro
Hematology (2021) Vol. 2021, Iss. 1, pp. 113-121
Open Access | Times Cited: 11

Showing 11 citing articles:

FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes
Eyleen de Poel, Sacha Spelier, Marne C. Hagemeijer, et al.
Journal of Cystic Fibrosis (2023) Vol. 22, Iss. 3, pp. 548-559
Open Access | Times Cited: 26
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option
Jeffrey H. Lipton, Tim H. Brümmendorf, Carlo Gambacorti‐Passerini, et al.
Blood Reviews (2022) Vol. 56, pp. 100968-100968
Open Access | Times Cited: 35
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Ehab Atallah, Michael J. Mauro, Andreas Hochhaus, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 9, pp. 6247-6262
Open Access | Times Cited: 13
Tyrosine kinase inhibitor discontinuation and reinitiation patterns in CML patients in the US: real-world evidence
Jyotirmoy Sarker, Ehab Atallah, Kathryn E. Flynn, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-6
Closed Access
Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Nidhi Mehra, Armon Varmeziar, Xinyu Chen, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4686-4686
Open Access | Times Cited: 18
In vivo imaging system (IVIS) therapeutic assessment of tyrosine kinase inhibitor-loaded gold nanocarriers for acute myeloid leukemia: a pilot study
Raluca-Andrada Munteanu, Adrian Bogdan Țigu, Richard Feder, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia
Özge Sönmez, Nurgül Özgür Yurttaş, İlker İhtiyaroğlu, et al.
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 24, Iss. 4, pp. 232-239
Closed Access | Times Cited: 2
Haematological Drugs Affecting Lipid Metabolism and Vascular Health
Antonio Parrella, Arcangelo Iannuzzi, Mario Annunziata, et al.
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1935-1935
Open Access | Times Cited: 4
ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity
Jenica N. Upshaw, Richard Travers, Iris Z. Jaffe
JACC CardioOncology (2022) Vol. 4, Iss. 3, pp. 384-386
Open Access | Times Cited: 3
The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia
M. N. Saez Perdomo, Ruth Stuckey, Elena González-Pérez, et al.
Hematology Reports (2024) Vol. 16, Iss. 1, pp. 140-150
Open Access
Chronic myeloid leukemia: where do we stand, where can we go?
Krzysztof Lewandowski, Jakub Lewandowski
Acta Haematologica Polonica (2022) Vol. 53, Iss. 3, pp. 153-165
Open Access | Times Cited: 1
Page 1

Scroll to top